Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

Agios Pharmaceuticals Inc AGIO reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency.

• Data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. 
• Long-term extension data demonstrate that previously reported effects of mitapivat on hemoglobin and transfusion burden were maintained over time. 
• Non-regularly transfused patients randomized to mitapivat maintained hemoglobin response for up to 19.5 months. Similarly, 35% of patients who switched from placebo to mitapivat achieved a hemoglobin response, maintained for the duration of follow-up. 
• All regularly transfused patients who achieved transfusion-free status with mitapivat treatment maintained the status through the extension study for up to 21.9 months.
• Related Link: Agios' Rare Anemia Drug Application Under FDA Priority Review.
• Price Action: AGIO shares closed at $31.67 on Monday.
• Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.